Presentation is loading. Please wait.

Presentation is loading. Please wait.

Nephrotic Syndrome Deputy Director Dept. of Nephrology

Similar presentations


Presentation on theme: "Nephrotic Syndrome Deputy Director Dept. of Nephrology"— Presentation transcript:

1 Nephrotic Syndrome Deputy Director Dept. of Nephrology
Farid Nakhoul M.D. Deputy Director Dept. of Nephrology Rambam Medical Ctr. Faculty of Medicine Haifa Tel: Fax:

2 Structure of the Glomerulus(1)
One of the central function of the kidney is to excrete low molecular weight water-soluble plasma waste products into the urine. Whereas macromolecules the size of albumin and larger are retained. The filtration of plasma occurs in specialized filtration units called Glomeruli.

3 Structure of the Glomerulus(2)
The glomerular filtration barrier consists of the three layers of the capillary wall: 1. The innermost fenestrated vascular endothelium. 2. The GBM: the GBM is regarded as a primary size and charge-selective molecular sieve of the glomerulus . The GBM contains type IV collagen, laminin, nidogen, and proteoglycans as its main components. 3. Podocyte cell layer facing the urinary space.

4

5

6

7 Proteinuria Is the halmark of glomerular disease !!

8 Clinical Evaluation of Glomerular disease
1. History 2. Physical Examination 3. Laboratory Studies 4. Imaging: Ultrasound 5. Renal Biopsy ( Open, Closed, Laparoscopic).

9 Proteinuria Asymptomatic Non-nephrotic Proteinuria (<3.5 gr Protein/day). - Glomerular - Non-glomerular Nephrotic Syndrome: Pathognomonic of glomerular disease

10 Non-Nephrotic Proteinuria
Defined as a urine protein excretion of less than 3.5 gr/d, and is absolutely characteristic of glomerular disease, but may occure in many non-glomerular parenchymal disease.

11 Clinical Classification
Isolated Hematuria Proteinuria / Nephrotic Syndrome Acute Nephritic Syndrome Rapidly Progressive Glomerulonephritis Chronic Glomerulonephritis

12 Clinical Features of Glomerular Diseases
Proteinuria Hematuria Edema Hypertension Renal Dysfunction

13 Evaluation of Proteinuria – General Practice

14

15 Quantifying protein excretion
Should perform quantitative measure in persistent proteinuria 24 hour urine collection Readily quantified Wide understanding Cumbersome Protein-to-creatinine ratio (PCR) Simple Validated

16 Nephrotic Syndrome Definition
Urinary protein level exceeding 3.5 gr per 1.73m2 of body-surface area/day. Hypoalbuminemia. Sodium retention (Edema-State). Hyperlipoproteinemia. Hypercoagulopathy

17

18

19 Prognosis Depends upon degree of proteinuria 20 year follow up:
Hypertension in 50% Renal Insufficiency in 40%

20 Diagnostic Approach 24 urine collection
Serum electrolytes, BUN, creatinine, lipid profile, serum albumin Serological work up - depends upon the clinical presentation - common serological tests done are ANA; Anti-ds DNA Complement levels (C3, C4) Hepatitis B and C serologies SPEP; UPEP, ANCA, anti GBM Abs Renal Ultrasound Renal Biopsy - Indications

21 Nephrotic Syndrome Primary Membranous Glomerulopathy
Focal Segmental Glomerulosclerosis Minimal Change Disease Membranoproliferative GN Secondary Diabetic glomerulosclerosis Paraproteinemia /Amyloidosis Lupus Nephritis

22

23

24

25 Nephrotic Syndrome Thromboembolic Complications
Major hazard of the nephrotic syndrome RVT( membranous GN) in 20-30% of adult patients, 10% are symptomatic: flank pain, gross hematuria Pulmonary emboli(Silent) DVT(frequent) Arterial thrombosis is less common Prophylaxis : Albumin< 2 gr, Uprotein>10 gr/d. decreased level of antithrombin III, Increased fibrinogen, Hypovolemia

26

27 Nephrotic Syndrome Infections
Decreased levels of immunoglobulin IgG Decreased the alternative complement factor B Pneumococcal peritonitis Recurrent Cellulitis

28 General Management Edema - salt restriction, diuretics
Hyperlipidemia - lipid lowering agents ACE/ARB - decrease Pgc and decrease proteinuria Renal protective Hypercoagulable - ASA Specific treatment based on biopsy

29

30

31 Minimal Change Disease MCD
Introduction and Definition

32 Minimal Change Disease
Pathogenesis - unknown, most likely autoimmune Treatment 85% respond to steroids If resistant to steroid may require cyclophosphamide

33 Minimal Change Nephropathy (MCD)
Minimal change disease (MCD) :is defined by the absence of histologic glomerular abnormality, other than evidence of epithelial cell foot process fusion (EM).

34 Minimal Change Disease MCD
Pathology

35

36 Minimal Change Disease

37 Nephrotic Syndrome Minimal Change Disease
Is the major cause of the nephrotic syndrome in children(85-90%) and 10% in adults Malignancies account for 10% of cases of idiopathic nephrotic syndrome in adults LM: Normal glomeruli EM: Fusion of the epithelial cell foot Processes ( KNB).

38 Minimal Change Disease MCD
Etiology and Pathogenesis

39 Minimal Change Disease
Idiopathic Secondary: Malignancy Drugs Infections

40

41 Minimal Change Disease MCD
Clinical manifestations

42 Minimal Change Nephropathy MCD
Patients with Minimal change disease present with edema that develops over a short period of time, with fluid retention exceeding 3% of the body weight. Up to two-thirds of presentation and relapses follow an infection, most commonly upper respiratory tract infection.

43 Minimal Change Nephropathy
Clinical Feature: Heavy proteinuria, low serum albumin, edema formation and elevated serum cholesterol. Normal urinary sediment Normal C3, C4 Negative ANA and Cryoglobulins MCD patients are at risk of venous thromboembolism. Hypovolemia and ARF, especially patients with diuretic therapy.

44 Minimal Change Disease
Natural History

45 Minimal Change Disease
There is a tendency for patients with MCD to run a relapsing-remitting course and this is more frequent in children. Long-term remission can be expected in 75% of initial responders who do not relapse within 6 months. MCD does not progress to Renal Failure

46 Membranous GN Definition

47 Membranous Nephropathy(MN)
Membranous Nephropathy is a glomerular disease in which immune deposits of IgG and complement components develop predominantly or exclusively on the subepithelial surface of the glomerular capillary wall. Deposition is associated with a marked increase in glomerular permeability to protein, which manifest clinically as nephrotic syndrome. The pathogenesis of human MN is not known.

48 Membranous Nephropathy
ETIOLOGY

49 Membranous Nephropathy
Most common cause of idiopathic nephrotic syndrome in Caucasian adults. Heavy proteinuria is common. Hypertension and azotemia develops as disease progresses. Increased incidence of renal vein thrombosis.

50 Membranous nephropathy
2nd most common cause of nephrotic syndrome in adults (~30%) Usually idiopathic Associated with Autoimmune diseases Hepatitis B Carcinoma Drugs (eg penicillamine, captopril, NSAID) Outcome very variable 1/3 spontaneous remission 1/3 partial remission or very slow progression 1/3 progressive renal impairment Higher incidence of thromboembolism Therapy very difficult

51 Membranous Nephropathy
Idiopathic Secondary GN: Immunological: -SLE, MCTD -Sjogren Syndrome Rheumatoid Arthritis Neoplasms: -Ca of lung -Ca of breast, Kidney Non-Hodgin Lymphoma

52 Membranous Nephropathy
Infectious: -Hepatitis B -Malaria -Schistosomiasis Medications: -NSAIDs, Gold, Penicillamine -Capoten

53 Pathology The pathologic feature of MN evolve from the initial formation of subepithelial immune complexes of IgG and complement. Initial stage on EM ranging from minimal change with only small deposits( stage 1) through the evolution to thickened basement membrane with resolution of deposits (stage IV).

54

55 Membranous Nephropathy

56 Membranous Nephropathy
Clinical manifestation

57 Membranous Nephropathy
Is the most common cause of the idiopathic nephrotic syndrome in adults(30-50%) Nephrotic Syndrome is the common presentation Hypertension 30% In children: 50% spontaneous remission, 10% to ESRD Stage 1 >>>good prognosis Stage 4>>>>bad Prognosis

58 Membranous Nephropathy
Natural History and Prognosis

59 Membranous GN The prognosis of untreated MN is somewhat worse in adults: 20% will have progressed to ESRD at 5-10 years followup. . Bad outcome: male, age>50, HTN, Pcr high at presentation. Recurrence after Renal Transplantation

60 Membranous Nephropathy
Treatment

61 Treatment Steroides Cyclosporine Imuran Cyclophosphamide Chlorambucil

62 Treatment of Membranous Nephropathy
Rule of 1/ /3 – Spontaneous remission 1/3 – Partial remission / slow deterioration 1/3 – Progress to ESRD Steroids alone are not very effective Methylprednisolone alternating with chlorambucil, Methylprednisolone alternating with cyclophosphamide. Cyclosporin

63 Focal Segmental Glomerulosclerosis
Introduction and Definition

64 Focal Segmental Glomerulosclerosis
Etiology and Pathogenesis

65 Focal Segmental Glomerulosclerosis (FSGS)
Primary (Idiopathic) Secondary: -Sickle cell disease -Heroin Nephropathy -Morbid obesity -HIV Nephropathy -Aging Kidney -Vesico-Ureteral Reflux - Pamidronate

66 FSGS Most common idiopathic nephrotic syndrome in adults (33%)
Increasing incidence More common in blacks Treatment very difficult

67 Focal Segmental Glomerulosclerosis
Most common primary renal disease in African-Americans Etiology: Idiopathic Drugs – Intravenous heroin Infections – HIV Others – reflux nephropathy, obesity Patient usually hypertensive. Usually progresses to ESRD over 5-20 years.

68 FSGS Pathology

69 Focal Segmental Glomerulosclerosis (FSGS)
FSGS is defined on histologic criteria by segmental capillary obliteration with increased mesangial matrix deposition, intracapillary hyaline deposits, and focal adhesions of the capillary tuft to Bowman’s capsule. Primary FSGS occur in patient with nephrotic syndrome in the absence of any of the known causes of secondary FSGS.

70

71

72 FSGS Associations Idiopathic Morbid obesity Heroin abuse HIV infection
Collapsing Mild Moderate Associations Idiopathic Morbid obesity Heroin abuse HIV infection NSAID (Minimal change disease) Normal

73 FSGS In FSGS, evidence for a circulating factor is more substantial, mainly based on the high incidence of recurrence following transplantation, with heavy proteinuria developing sometimes within hours. Plasma exchange can lead to remission in tranplant recurrence of FSGS.

74 FSGS Clinical Manifestations

75 FSGS Typically patients present with edema that develops over a short period of time. Very rapid onset of nephrotic syndrome Microscopic hematuria 14-30% Arterial Hypertension especially with renal insufficiency. Increased incidence pf venous thromboembolism.

76 Focal Segmental Glomerulosclerosis
Microscopic Hematuria Proteinuria >>20-30 gram/daily Both children and adults usually develops ESRD 5-20 yrs from presentation. Idiopathic FSGS may recur in the transplanted kidney with severe proteinuria and Nephrotic Syndrome and rapid course to ESRD.

77 Collapsing FSGS Collapsing FSGS is a histologic variant of FSGS characterized by extensive focal or global glomerular capillary tuft collapse, podocyte hypertrophy and hyperplasia. Varying degree of tubulointerstitial injury. African Americans Severe nephrotic syndrome at presentation, steroid resistance, and rapid developing ESRD (median time of 13 month).

78 FSGS-Treatment 1mg/kg Prednisone daily for 6 month PO Cyclosporine
Cytotoxic Treatment (Cytoxan, Imuran) Symptomatic treatment with ACEI CellCept (Mycophenolate Mofetil).

79 Nephrotic Syndrome Secondary To Systemic Disease
Diabetes Mellitus—Type I, Type II Amyloidosis

80 Diabetes Mellitus INTRODUCTION

81 Diabetic Nephropathy Diabetic Nephropathy is a common problem that is most likely to occur in patients who have worse glycemic control, Hypertension, glomerular hyperfiltration, Blacks, Mexican, or Pima Indian.

82 Diabetic Nephropathy Diabetic nephropathy is a leading cause of end-stage renal disease (ESRD) in Western societies Diabetic nephropathy is a clinical syndrome characterized by persistent albuminuria(>300 mg/24hr or >200ug/min) on at least two occasions separated by 3-6 months. Patients invariably develop hypertension, progressive increase in proteinuria, and decline in GFR.

83 Diabetic Nephropathy Major Risk Factors For DN
1. Genetic Susceptibility 2. Arterial Hypertension 3. Increased glomerular filtration rate 4. Worse Glycemic Control 5. Blacks, Pima Indian

84 Microalbuminuria . Increased protein excretion is the earlies clinical finding of diabetic nephropathy. The normal rate of albumin excretion is less than 20 mg/day; persistent values between 30 and 300 mg/day( 20 to 200 ug/min) in a patient with diabetes is called Microalbuminuria .

85 Microalbuminuria and correlation with DN
Great attention to control of both hyperglycemia and hypertension (with ACEI) may also contribute to the apparent improvement in the course of the disease. Patient who progress are more likely to have higher HbA1c values and higher blood pressure than non progresses. The incidence of overt hypertension is approximately 15 to 25 percent in all patients with microalbuminuria and much higher as the patient progress to overt nephropathy.

86 Epidemiology Type 1 diabetic nephropathy, occur in 30-40% of patients with type 1 diabetes after years with diabetes In type 2 diabetes, the cumulative incidence of nephropathy is similar to that seen in type 1 , 25% at 20 years after diagnosis. Since type 2 diabetes is times more common than type 1, the prevalence of type 2 diabetic nephropathy is substantialy higher.

87 Renal Pathology The kidneys of patients with diabetes are, on average larger than those of nondiabetic control subjects(15%). Nodular glomerular intercapillary lesions, described by Kimmelsteil and Wilson. Diffuse glomerular lesion is more frequent than the nodular lesion, with an incidence of over 90% for patients with type 1 DM of over 10 years duration and an incidence of 25-50% in patients with type 2 DM.

88 Diabetic Nephropathy

89 Diabetic Nephropathy Most common cause of nephrotic syndrome in adults. Leading cause of ESRD in USA 30% of patients with Type I and 20% of patients with Type II DM develop diabetic nephropathy. Initially microalbuminuria followed by heavy proteinuria and decline in renal function. Diagnosis usually made on clinical grounds and biopsy not needed.

90 Clinical Manifestations and Natural History
Diabetic Nephropathy Clinical Manifestations and Natural History

91

92

93 Treatment of Diabetic Nephropathy
Blood glucose control Control of hypertension Use of ACE inhibitors/ARBs Control of hyperlipidemia Smoking cessation Protein Restriction

94 Nephrotic Syndrome Secondary To Systemic Disease: Amyloidosis
-Primary Amyloidosis -Secondary Amyloidosis

95 Amyloidosis The Amyloidosis are a group of disorders in which soluble proteins aggregate and deposit extracellulary in tissues as insoluble fibrils, causing progressive organ dysfunction. The kidney is one of the most frequent sites of amyloid deposition in AA, AL, and several of the hereditary amyloidoses.

96 Amyloidosis Amyloidosis is defined by the ability of a variety of proteins to form B-pleated sheets. These fibrils can be identified on biopsy specimens both by their characteristic appearance on electron microscopy and by their ability to bind Congo Red(leading to green birefringence under polarized light) and thioflavine-T (producing an intense yellow-green fluorescence).

97

98 Amyloidosis Amyloid A in secondary amyloidosis
Immunoglobulin light chains in primary amyloidosis B2-microglobulin in dialysis-patients associated arthropathy Amyloid beta protein in Alzheimer’s disease

99 Amyloidosis Renal involvement occurs in over 90% of patients with either primary or secondary amyloidosis. Primary forms(> 90%) is a plasma cell dyscrasia and may be associated with MM. Light Chain Deposition Disease (LCDD) is a disorder of similar pathogenesis. The abnormal protein do not form the B-pleated amyloid fibrils. Secondary amyloidosis is a consequence of chronic inflammatory diseases such as : Rheumatoid arthritis, FMF, Osteomyelitis, Hypernephroma, PID.

100 Amyloidosis-Secondary
Clinically evident renal involvement occurs only in primary or secondary amyloidosis Secondary amyloidosis is associated with increased hepatocyte production of the acute phase reactant serum amyloidosis A (SAA); this process may be stimulated by the release of cytokines ( Interleukin-1) from activated macrophages. Cleavage in circulating monocyte/macrophages results in the generation of smaller fragments, called AA protein, that can then deposit in the tissue.

101 Primary Amyloidosis (AL)
The fibrils in AL consist of segments of the variable portions of monoclonal light chains AL Amyloidosis is a plasma cell dyscrasia in which the malignant characteristic of M.M are usually absent and circulating light chains are frequently demonstrated . Only a minority of patients who produce an excessive amounts of light-chains (as M.M) develop amyloidosis. Lambda light-chains are much more likely to produce amyloidosis than Kappa light chains.

102 Dysproteinemia Myeloma Cast Nephropathy
Path shows multiple intraluminal proteinaceous casts Pathogenesis Disorder of plasma cells with overproduction the antibody light chain Treatment Hydration, plasmapheresis to remove the abnormal protein and chemotherapy to suppress plasma cells

103 Myeloma Cast Nephropathy

104 Light Chain Deposition Disease
Amyloid protein produced in plasma cell dyscrasias is preferentially lamda light chains Kappa chain can occur and termed light chain deposition disease Kappa chain deposits tend to deposit in tubules and glomeruli, spare vessels Kappa more aggressive than lambda

105 Diagnosis Documentation of tissue deposition of amyloid fibrils.
Kidney biopsy> 90% of patients Abdominal fat pad> 80-90% Rectal> 50-80% Gingival>60% Once the DX of primary amyloidosis is made, the patient should be evaluated for M.M ! ! !

106 Pathology On light microscopy> >>Diffuse deposition of amorphous hyaline material in the mesangium and then capillary loops. Amyloid deposition in the glomeruli can result in the formation of nodules. Congo Red induces green birefringence when viewed under polarized light. Immunofluorescence for immunoglobulin and complement is negative.

107 Key things to Remember Amyloid is hyaline, eosinophils, Congo Red + Green Birefringence when polarized Small non-branching fibrils on EM

108

109

110 Amyloidosis More common in elderly Two main types of renal amyloid
Normal More common in elderly Two main types of renal amyloid AL amyloid AA amyloid

111 Clinical Presentation
Non-specific symptoms, Fatigue, Weight loss, Anemia Proteinuria, edema>>>Nephrotic Syndrome Carpal tunnel syndrome Peripheral neuropathy Hepato-Splenomegaly, Macroglossia Renal insufficiency Tubular involvement : RTA, NDI, Hyperkalemia

112 Course and Treatment Prognosis depend on type of amyloidosis
MM= bad Prognosis In primary Amyloidosis usually progress slowly to CRF Prednisone an Melphalan is the major mode of therapy for primary amyloidosis Colchicine in AL, AA amyloidosis In AA the progression depend upon the ability to control the underlying disease.

113

114 Asymptomatic Non-Nephrotic Proteinuria
Overflow Proteinuria: Multiple Myeloma -Light Chain Tubular Proteinuria: Tubulointerstitial dis. < 2 gr/day Glomerular proteinuria

115 Treatment Steroid Treatment induces remission in almost all patients with MCD. Adults usually biopsied before treatment (KNB). Controll first volume overload (Diuretics).

116 Treatment Steroid responsive Steroid dependent Frequent relapsers


Download ppt "Nephrotic Syndrome Deputy Director Dept. of Nephrology"

Similar presentations


Ads by Google